Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* kidney transplantation \>/=6 months ago~* on mycophenolic acid-based, calcineurininhibitor-free therapy for \>/=3 months, \>/=1 month on stable dose~* co-therapy with 5mg prednisone for \>/=1 month~Exclusion Criteria:~* active gastrointestinal ulcus~* severe diarrhea od gastrointestinal disease~* severe impairment of renal function~* current malignancy~* Lesch-Nyhan- or Kelley-Seegmiller-Syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MMF, Prednisone (Type: EXPERIMENTAL): Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
- EC-MPS (Type: ACTIVE_COMPARATOR): Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).